Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Preferred Shares (2017 - 2021)

Avalo Therapeutics filings provide 5 years of Preferred Shares readings, the most recent being $1000.0 for Q1 2021.

  • On a quarterly basis, Preferred Shares fell 20.45% to $1000.0 in Q1 2021 year-over-year; TTM through Mar 2021 was $1000.0, a 20.45% decrease, with the full-year FY2020 number at $1000.0, down 65.0% from a year prior.
  • Preferred Shares hit $1000.0 in Q1 2021 for Avalo Therapeutics, roughly flat from $1000.0 in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $2857.0 in Q4 2018 to a low of $4.0 in Q1 2017.
  • Median Preferred Shares over the past 5 years was $1257.0 (2020), compared with a mean of $1672.0.
  • Biggest five-year swings in Preferred Shares: changed 0.0% in 2019 and later tumbled 65.0% in 2020.
  • Avalo Therapeutics' Preferred Shares stood at $4.0 in 2017, then soared by 71325.0% to $2857.0 in 2018, then changed by 0.0% to $2857.0 in 2019, then crashed by 65.0% to $1000.0 in 2020, then changed by 0.0% to $1000.0 in 2021.
  • The last three reported values for Preferred Shares were $1000.0 (Q1 2021), $1000.0 (Q4 2020), and $1257.0 (Q3 2020) per Business Quant data.